Antiphospholipid syndrome primary prevention: Difference between revisions
Feham Tariq (talk | contribs) No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Antiphospholipid syndrome}} | {{Antiphospholipid syndrome}} | ||
{{CMG}} {{AE}} | {{CMG}} {{AE}}{{FT}} | ||
==Overview== | ==Overview== | ||
==Primary Prevention== | ==Primary Prevention== | ||
In addition to anticoagulation, attention should be paid to minimizing the contribution of reversible risk factors for recurrent thrombosis. During the perioperative period, this may include minimizing the period when patients are off anticoagulation, initiating early ambulation, and other measures to reduce venous stasis | |||
[[Randomized controlled trial]]s have addressed the secondary prevention of thromboses. These trials include APLASA<ref name="pmid17599766">{{cite journal| author=Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L et al.| title=Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. | journal=Arthritis Rheum | year= 2007 | volume= 56 | issue= 7 | pages= 2382-91 | pmid=17599766 | doi=10.1002/art.22663 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17599766 }} </ref>, | [[Randomized controlled trial]]s have addressed the secondary prevention of thromboses. These trials include APLASA<ref name="pmid17599766">{{cite journal| author=Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L et al.| title=Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. | journal=Arthritis Rheum | year= 2007 | volume= 56 | issue= 7 | pages= 2382-91 | pmid=17599766 | doi=10.1002/art.22663 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17599766 }} </ref>, | ||
Revision as of 20:14, 4 April 2018
|
Antiphospholipid syndrome Microchapters |
|
Differentiating Antiphospholipid syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Antiphospholipid syndrome primary prevention On the Web |
|
American Roentgen Ray Society Images of Antiphospholipid syndrome primary prevention |
|
Risk calculators and risk factors for Antiphospholipid syndrome primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Feham Tariq, MD [2]
Overview
Primary Prevention
In addition to anticoagulation, attention should be paid to minimizing the contribution of reversible risk factors for recurrent thrombosis. During the perioperative period, this may include minimizing the period when patients are off anticoagulation, initiating early ambulation, and other measures to reduce venous stasis Randomized controlled trials have addressed the secondary prevention of thromboses. These trials include APLASA[1],
References
- ↑ Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L; et al. (2007). "Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals". Arthritis Rheum. 56 (7): 2382–91. doi:10.1002/art.22663. PMID 17599766.